메뉴 건너뛰기




Volumn 61, Issue 12, 2001, Pages 1835-1881

Atorvastatin: An updated review of its pharmacological properties and use in dyslipidaemia

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; AMINOTRANSFERASE; ATORVASTATIN; BEZAFIBRATE; CHOLESTEROL; COLESTIPOL; CREATINE KINASE; CYCLOSPORIN; ERYTHROMYCIN; ETHINYLESTRADIOL; FENOFIBRATE; FLUINDOSTATIN; FUSIDIC ACID; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; LIPID; LOPINAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINIC ACID; ORAL CONTRACEPTIVE AGENT; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

EID: 0034770421     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161120-00012     Document Type: Article
Times cited : (148)

References (242)
  • 1
    • 0030947754 scopus 로고    scopus 로고
    • Atorvastatin: A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias
    • May
    • (1997) Drugs , vol.53 , pp. 828-847
    • Lea, A.P.1    McTavish, D.2
  • 2
    • 0033588470 scopus 로고    scopus 로고
    • Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
    • (1999) Life Sci , vol.65 , Issue.13 , pp. 1329-1337
    • Moghadasian, M.H.1
  • 4
    • 0028200059 scopus 로고
    • Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase
    • (1994) Am J Cardiol , vol.73 , Issue.SUPPL. D
    • Blum, C.B.B.1
  • 5
    • 0029818771 scopus 로고    scopus 로고
    • Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease
    • Sep
    • (1996) Clin Cardiol , vol.19 , pp. 683-689
    • Rackley, C.E.1
  • 6
    • 0026567257 scopus 로고
    • Hepatic and non-hepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: Comparison with selected HMG-CoA reductase inhibitors
    • Jan 24
    • (1992) Biochim Biophys Acta , vol.1123 , pp. 133-144
    • Bocan, T.M.A.1    Ferguson, E.2    McNally, W.3
  • 11
    • 0027995418 scopus 로고
    • Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: A biochemical and morphological evaluation
    • Nov
    • (1994) Atherosclerosis , vol.111 , pp. 127-142
    • Bocan, T.M.A.1    Mazur, M.J.2    Mueller, S.B.3
  • 12
    • 0029113047 scopus 로고
    • Lipid-lowering activity of atorvastatin and lovastatin in rodent species: Triglyceride-lowering in rat correlates with efficacy in LDL animal models
    • Oct
    • (1995) Atherosclerosis , vol.117 , pp. 237-244
    • Krause, B.R.1    Newton, R.S.2
  • 17
    • 0033973214 scopus 로고    scopus 로고
    • Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: Effect of triglyceride reductions with atorvastatin
    • (2000) Metabolism , vol.49 , Issue.2 , pp. 167-177
    • Le, N.-A.1    Innis-Whitehouse, W.2    Li, X.3
  • 31
    • 0032478236 scopus 로고    scopus 로고
    • Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia
    • Mar
    • (1998) Atherosclerosis , vol.137 , pp. 197-203
    • Simons, L.A.1    Sullivan, D.2    Simons, J.3
  • 35
    • 0035830412 scopus 로고    scopus 로고
    • Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance
    • Jan 2
    • (2001) Circulation , vol.103 , pp. 113-118
    • Feron, O.1    Dessy, C.2    Desager, J.-P.3
  • 39
    • 0003339920 scopus 로고    scopus 로고
    • Effect of the new HMG-CoA reductase inhibitor atorvastatin on human vascular cell growth in mono- and cocultures in comparison to lovastatin
    • Aug
    • (1997) Eur Heart J , vol.18 , Issue.ABSTR. SUPPL. , pp. 37
    • Axel, D.I.1    Riessen, R.2    Runge, H.3
  • 41
    • 0002970719 scopus 로고    scopus 로고
    • Lipid-lowering and anti-aggregatory efficacy of atorvastatin in coronary heart disease patients with combined hyperlipidemia
    • May 24
    • (1999) Atherosclerosis , vol.144 , Issue.SUPPL. 1 , pp. 24
    • Viigimaa, M.1    Valkman, R.2
  • 44
    • 4243262732 scopus 로고    scopus 로고
    • Effects of atorvastatin treatment on global fibrinolytic capacity, apoptosis, and leukocyte activation in patients with coronary artery disease
    • Feb
    • (2001) J Am Coll Cardiol , vol.37 , Issue.SUPPL. A
    • Atalar, E.1    Acil, T.2    Aytemir, K.3
  • 45
    • 0032126266 scopus 로고    scopus 로고
    • HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion development in the cholesterol-fed rabbit
    • Jul
    • (1998) Atherosclerosis , vol.139 , pp. 21-30
    • Bocan, T.M.1    Mueller, S.B.2    Brown, E.Q.3
  • 47
    • 0002973108 scopus 로고    scopus 로고
    • Atorvastatin decreases elevated levels of C-reactive protein in patients with cardiovascular disease and mixed dyslipidaemia: The ATOMIX Study
    • Aug-Sep
    • (2000) Eur Heart J , vol.21 , Issue.SUPPL. , pp. 497
    • Aristegui, R.1    Gomez-Gerique, J.A.2    Gil, R.3
  • 48
    • 0035173483 scopus 로고    scopus 로고
    • Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia
    • Jan
    • (2001) Thromb Haemost , vol.85 , pp. 47-51
    • Joukhadar, C.1    Klein, N.2    Prinz, M.3
  • 55
    • 0032032592 scopus 로고    scopus 로고
    • Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
    • [published erratum appears in Am J Cardiol 1998 Jul 1;82(1): 128] Mar 1
    • (1998) Am J Cardiol , vol.81 , pp. 582-587
    • Jones, P.1    Kafonek, S.2    Laurora, I.3
  • 57
    • 0030967489 scopus 로고    scopus 로고
    • Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia
    • Atorvastatin Study Group I. Jun 1
    • (1997) Am J Cardiol , vol.79 , pp. 1475-1481
    • Davidson, M.1    McKenney, J.2    Stein, E.3
  • 60
    • 0031195278 scopus 로고    scopus 로고
    • A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia
    • Jul 1
    • (1997) Am J Cardiol , vol.80 , Issue.1 , pp. 39-44
    • Dart, A.1    Jerums, G.2    Nicholson, G.3
  • 61
    • 0035941786 scopus 로고    scopus 로고
    • Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): A prospective, randomised, double-blind trial
    • Feb 24
    • (2001) Lancet , vol.357 , pp. 577-581
    • Smilde, T.J.1    Van Wissen, S.2    Wollersheim, H.3
  • 74
    • 0032513756 scopus 로고    scopus 로고
    • Association of fibrinogen, C-reactive protein, albumin or leukocyte count with coronary artery disease: Meta-analyses of prospective studies
    • (1998) JAMA , vol.279 , pp. 1477-1482
    • Danesh, J.1    Collins, R.2    Appleby, P.3
  • 77
    • 0032499382 scopus 로고    scopus 로고
    • Statins and fibrinogen
    • May 9; discussion 1431-2
    • (1998) Lancet , vol.351 , pp. 1430
    • Black, D.M.1
  • 105
    • 0035897696 scopus 로고    scopus 로고
    • Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in adults (Adult Treatment Panel III)
    • May 16
    • (2001) JAMA , vol.285 , Issue.19 , pp. 2486-2497
  • 106
    • 0028072711 scopus 로고
    • Prevention of coronary heart disease in clinical practice: Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension
    • Oct
    • (1994) Eur Heart J , vol.15 , pp. 1300-1331
    • Pyörälä, K.1    De Backer, G.2    Graham, I.3
  • 112
  • 118
    • 0000474621 scopus 로고    scopus 로고
    • ZD4522 is superior to atorvastatin in decreasing low density lipoprotein cholesterol and increasing high density lipoprotein cholesterol in patients with type IIa or IIb hypercholesterolemia
    • Feb
    • (2001) J Am Coll Cardiol , vol.37 , Issue.2 SUPPL. A
    • Davidson, M.H.1    Ma, P.T.S.2    Stein, E.3
  • 120
    • 0033995230 scopus 로고    scopus 로고
    • Achievement of target plasma cholesterol levels in hypercholesterolaemic patients being treated in general practice
    • (2000) Atherosclerosis , vol.149 , Issue.1 , pp. 199-205
    • Barter, P.J.1    O'Brien, R.C.2
  • 122
  • 126
    • 0031787156 scopus 로고    scopus 로고
    • Randomised, double-blind, parallel-group trial of atorvastatin and fluvastatin on plasma lipid levels in patients with untreated hyperlipidaemia
    • (1998) Br J Cardiol , vol.5 , Issue.11 , pp. 597-602
    • Schuster, H.1    Berger, J.2    Luft, F.C.3
  • 129
  • 133
    • 0032004986 scopus 로고    scopus 로고
    • A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia
    • Collaborative Atorvastatin Study Group. Feb
    • (1998) Am J Med , vol.104 , pp. 137-143
    • McKenney, J.M.1    McCormick, L.S.2    Weiss, S.3
  • 137
    • 0034077628 scopus 로고    scopus 로고
    • Diabetic dyslipidaemia: Current treatment recommendations
    • (2000) Drugs , vol.59 , Issue.5 , pp. 1101-1111
    • Best, J.D.1    O'Neal, D.N.2
  • 140
    • 0032724923 scopus 로고    scopus 로고
    • Strategies for the management of diabetic dyslipidaemia
    • (1999) Drugs , vol.58 , Issue.SUPPL. 1 , pp. 47-51
    • Taskinen, M.-R.1
  • 143
    • 0002969193 scopus 로고    scopus 로고
    • Does the presence of either concurrent hypertension or non-insulin-dependent diabetes mellitus affect the efficacy and safety of atorvastatin in patients with hyperlipidaemia?
    • Apr
    • (1998) Am J Hypertens , vol.11 , Issue.PART. 2 , pp. 75
    • Black, D.M.1    Bakker-Arkema, R.2    Heinonen, T.3
  • 144
    • 4243816042 scopus 로고    scopus 로고
    • The Can-ADA Study: Do lipid parameters respond differently to atorvastatin therapy in ischemic heart disease subjects with and without type 2 diabetes?
    • Sep
    • (2000) Can J Cardiol , vol.16 , Issue.SUPPL. F
    • Bogaty, P.1    Leiter, L.2    Murray, P.3
  • 147
    • 23544460682 scopus 로고    scopus 로고
    • The ASSET Investigators. The efficacy and safety of atorvastatin versus simvastatin in mixed dyslipidemic patients with type 2 diabetes mellitus during 54 weeks
    • Jun
    • (2001) Diabetes , vol.50 , Issue.SUPPL. 2
    • Insull W., Jr.1
  • 148
    • 0035431019 scopus 로고    scopus 로고
    • The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia. The DALI Study: A double-blind, randomised placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia
    • Aug
    • (2001) Diabetes Care , vol.24 , Issue.8 , pp. 1335-1341
  • 150
    • 0032772992 scopus 로고    scopus 로고
    • Atorvastatin increases low-density lipoprotein size and enhances high-density lipoprotein cholesterol concentration in male, but not in female patients with familial hypercholesterolemia
    • Sep
    • (1999) Atherosclerosis , vol.146 , pp. 167-174
    • Hoogerbrugge, N.1    Jansen, H.2
  • 154
    • 0031904071 scopus 로고    scopus 로고
    • Effects of atorvastatin on serum lipids of patients with familial hypercholesterolaemia
    • Aug
    • (1998) J Intern Med , vol.244 , pp. 143-147
    • Hoogerbrugge, N.1
  • 156
    • 0034106943 scopus 로고    scopus 로고
    • A multicenter, open-label, randomized study comparing the efficacy of atorvastatin versus usual care in reducing refractory hypercholesterolemia in high-risk patients to target levels
    • (2000) Curr Ther Res Clin Exp , vol.61 , Issue.4 , pp. 175-190
    • Habib, G.1    Paillard, F.2    Charpentier, G.3
  • 157
    • 0031876986 scopus 로고    scopus 로고
    • Comparison of atorvastatin alone versus simvastatin ± cholestyramine in the management of severe primary hypercholesterolaemia (the Six Cities Study)
    • Jun
    • (1998) Aust N Z J Med , vol.28 , pp. 327-333
    • Simons, L.A.1
  • 158
    • 0031692691 scopus 로고    scopus 로고
    • Treating patients with documented atherosclerosis to National Cholesterol Education Program - Recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin
    • Sep
    • (1998) J Am Coll Cardiol , vol.32 , pp. 665-672
    • Brown, A.S.1    Bakker-Arkema, R.G.2    Yellen, L.3
  • 159
    • 0345034610 scopus 로고    scopus 로고
    • Safety of low-density lipoprotein cholesterol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial)
    • Jul 1
    • (1999) Am J Cardiol , vol.84 , pp. 7-13
    • März, W.1    Wollschläger, H.2    Klein, G.3
  • 160
    • 0032748231 scopus 로고    scopus 로고
    • An assessment of the efficacy of atorvastatin in treating patients with dyslipidaemia to target LDL-cholesterol goals: The Atorvastatin Matrix Study
    • (1999) Int J Clin Pract , vol.53 , Issue.7 , pp. 509-513
    • McVey, D.1    Patel, H.2    Eminton, Z.3
  • 162
    • 0035371373 scopus 로고    scopus 로고
    • Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidaemia and cardiovascular disease or risk factors for cardiovascular disease: The Women's Atorvastatin Trial on Cholesterol (WATCH)
    • (2001) Am Heart J , vol.141 , pp. 949-956
    • McPherson, R.1    Angus, C.2    Murray, P.3
  • 163
    • 0035943069 scopus 로고    scopus 로고
    • Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease
    • (2001) Circulation , vol.104 , pp. 387-392
    • Schartl, M.1    Bocksch, W.2    Koschyk, D.3
  • 164
    • 0035804846 scopus 로고    scopus 로고
    • Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: A randomized controlled trial
    • Apr 4
    • (2001) JAMA , vol.285 , Issue.13 , pp. 1711-1718
    • Schwartz, G.G.1    Olsson, A.G.2    Ezekowitz, M.D.3
  • 165
    • 0033536298 scopus 로고    scopus 로고
    • Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators
    • Jul 8
    • (1999) N Engl J Med , vol.341 , pp. 70-76
    • Pitt, B.1    Waters, D.2    Brown, W.V.3
  • 166
    • 0002891617 scopus 로고    scopus 로고
    • Can aggressive lipid-lowering therapy provide additional clinical benefit? Subgroup analysis of the Atorvastatin VErsus Revascularization Treatments (AVERT) trial
    • Aug-Sep
    • (2000) Eur Heart J , vol.21 , Issue.SUPPL. , pp. 157
    • Brown, W.V.1    Avert, I.2
  • 197
    • 0033044791 scopus 로고    scopus 로고
    • Cost of treating to a modified European Atherosclerosis Society LDL-C target. Comparison of atorvastatin with fluvastatin, pravastatin and simvastatin
    • Mar
    • (1999) Clin Drug Invest , vol.17 , Issue.3 , pp. 185-193
    • Smith, D.G.1    Leslie, S.J.2    Szucs, T.D.3
  • 198
    • 7344240413 scopus 로고    scopus 로고
    • The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients: A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin
    • (1998) Pharmacoeconomics , vol.14 , Issue.1 , pp. 59-70
    • Koren, M.J.1    Smith, D.G.2    Hunninghake, D.B.3
  • 201
    • 0002895329 scopus 로고    scopus 로고
    • The cost-effectiveness of statins: Evidence from the ACCESS trial
    • Mar-Apr
    • (2001) Value Health , vol.4 , Issue.2 , pp. 109
    • Smith, D.G.1
  • 202
    • 0027987849 scopus 로고
    • Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study Group (4S)
    • (1994) Lancet , vol.344 , pp. 1383-1389
  • 203
    • 0035077896 scopus 로고    scopus 로고
    • Cost-minimization analysis of simvastatin versus atorvastatin for maintenance therapy in patients with coronary or peripheral vascular disease
    • (2001) Clin Ther , vol.23 , Issue.2 , pp. 276-283
    • Attanasio, E.1    Russo, P.2    Allen, S.E.3
  • 206
    • 0027731644 scopus 로고
    • Adverse reactions profile: 10. simvastatin and pravastatin
    • (1990) Prescr J , vol.33 , pp. 217-220
    • Thompson, G.R.1
  • 209
    • 0034052167 scopus 로고    scopus 로고
    • Lipid lowering in the patient at risk - The next decade of discovery
    • (2000) Br J Cardiol , vol.7 , Issue.4 , pp. 223-230
    • Holme, I.1
  • 210
    • 0023025526 scopus 로고
    • Is the relationship between serum cholesterol and the risk of premature death from coronary heart disease continuous or graded? Findings in 356,222 screenees of the Multiple Risk Factor Intervention Trial (MRFIT)
    • (1986) JAMA , vol.256 , pp. 2823-2828
    • Stamler, M.1    Wentworth, D.2    Neaton, J.D.3
  • 213
    • 0032487931 scopus 로고    scopus 로고
    • Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
    • (1998) N Engl J Med , vol.339 , pp. 1349-1357
  • 215
    • 0032572086 scopus 로고    scopus 로고
    • Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TEXCAPS
    • (1998) JAMA , vol.279 , pp. 1615-1622
    • Downs, J.R.1    Clearfield, M.2    Weis, S.3
  • 216
    • 0035825934 scopus 로고    scopus 로고
    • Pro and con: Low-density lipoprotein cholesterol lowering is and will be the key to the future of lipid management
    • Mar
    • (2001) Am J Cardiol , vol.8 , Issue.87 SUPPL. 5A
    • Pedersen, T.R.1
  • 217
    • 0034918812 scopus 로고    scopus 로고
    • Risk factors for a major coronary event after myocardial infarction in the Scandianavian Simvastatin Survival Study (4S): Impact of predicted risk on the benefit of cholesterol-lowering treatment
    • Jul
    • (2001) Eur Heart J , vol.22 , Issue.13 , pp. 1119-1127
    • Wilhelmsen, L.1    Pyorala, K.2    Wedel, H.3
  • 218
    • 0034085446 scopus 로고    scopus 로고
    • Aggressive lipid-lowering initiation abates new cardiac events (ALLIANCE)-rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease
    • (2000) Am J Cardiol , vol.86 , Issue.2 , pp. 250-252
    • Isaacsohn, J.L.1    Davidson, M.H.2    Hunninghake, D.3
  • 220
    • 0000869291 scopus 로고    scopus 로고
    • A 4-year, placebo-controlled study of atorvastatin as prevention of CHD endpoints in patients with non-insulin dependent diabetes mellitus
    • May
    • (1997) Diabetes , vol.46 , Issue.SUPPL. 1 , pp. 363
    • Gmerek, A.1    McLain, R.2    Nawrocki, J.3
  • 226
    • 0035029222 scopus 로고    scopus 로고
    • Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolaemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial
    • (2001) Am Heart J , vol.141 , pp. 722-726
    • Raggi, P.1    Callister, T.Q.2    Davidson, M.3
  • 227
    • 0002967207 scopus 로고    scopus 로고
    • Assessing the effects of statins on atherosclerosis progression using intravascular ultrasound: Rationale and design of the REVERSAL study
    • (2001) Atherosclerosis , vol.2 , Issue.2 SUPPL. , pp. 51-52
    • Nissen, S.1
  • 230
    • 0034533427 scopus 로고    scopus 로고
    • CAVEAT: A randomised, double-blind, parallel group evaluation of cerivastatin 0.4mg and 0.8mg compared to atorvastatin 10mg and 20mg once daily in patients with combined (type IIB) dyslipidaemia
    • (2000) Br J Cardiol , vol.7 , Issue.12 , pp. 780-786
    • Ma, P.1    Hegele, R.2    Yale, J.F.3
  • 234
    • 0034003329 scopus 로고    scopus 로고
    • Should reductase inhibitor therapy to lower cholesterol be instituted in the setting of an acute coronary event? [1]
    • (2000) Atherosclerosis , vol.149 , Issue.1 , pp. 215-216
    • Goldstein, M.R.1
  • 236
    • 0034119417 scopus 로고    scopus 로고
    • Is a mechanical or a metabolic approach superior in the treatment of coronary disease? Results of the Atorvastatin Versus Revascularization (AVERT) Trial
    • (2000) Eur Heart J , vol.21 , Issue.13 , pp. 1029-1031
    • Waters, D.1
  • 237
    • 0032554676 scopus 로고    scopus 로고
    • Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
    • (1998) Circulation , vol.97 , pp. 1440-1445
  • 238
    • 0032554688 scopus 로고    scopus 로고
    • Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events Trial
    • (1998) Circulation , vol.97 , pp. 1446-1452
    • Sacks, F.M.1    Maye, L.A.2    Davis, B.R.3
  • 240
  • 241


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.